AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02854722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium-vitamin D3
Description: Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
Study NCT02854722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium-vitamin D3
Description: Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
Study NCT05395377 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers, Reimagined
Description: Participants in this group were provided with an online access code to enroll in WW and could choose the format of their choice- group, online, and/or smartphone app.
Study NCT05395377 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPP or RDN Counseling + Medication
Description: Participants met with a weight management specialist to receive weight loss medications, as well as, receiving either the DPP or Registered Dietitian coaching. Medications utilized in this study were Phentermine and Metformin. Metformin was prescribed if the participant could not tolerate Phentermine.
Study NCT05395377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric Surgery Evaluation
Description: Participants (BMI > 40) were offered a consultation with the bariatric surgical program that requires lifestyle weight management during the first 6 months. Participants were also able to choose to receive one of the other 4 intervention options in the first six months prior to consideration for bariatric surgery.
Study NCT02241226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perfect Health Course
Description: The Perfect Health course as taught at the Chopra Center for Wellbeing
Study NCT04489095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrophysiology Study
Description: After informed consent is obtained, patient will undergo TAVR as per usual standard of care. Using the same femoral vein access as is used standard for a portion of the TAVR procedure, an EPS will be performed during the TAVR procedure, immediately before and after valve implantation. The patient will recover on a general telemetry floor as per usual care, and the next day will undergo another EPS. This is not uncommonly done clinically for some patients after TAVR. At that point, based on the baseline EKG, intra-procedure findings, and EPS findings, the patient will either have a pacemaker implanted, a 30-day event monitor ordered, or neither of the above.
Study NCT01347021 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sacrospinous colpopexy versus high uterosacral colpopexy
Description: Women with uterine prolapse grade III or IV were randomly allocated to the sacrospinous colpopexy or high uterosacral colpopexy with vaginal hysterectomy.Before the surgery P-Qol questionnaire were completed and urogynecological examination include de POP-Q system was done. All patients underwent clinical check-ups 1, 6 and 12 months postoperatively. Each check-up included clinical examination and questionnaire.
Study NCT01892475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive-based physical activity program
Description: Drivers will be offered rewards valued at a day's rental for meeting daily step targets over the specified number of days each month from Months 1 to 4, where steps will be tracked by a step counter. They will also be offered incentives for meeting the following criteria:~1. Accurately predicting step target attainment the following months (SGD10)~2. Wearing and providing step data over the month (SGD10 and a chance to win 1 of 3 cash prizes valued at SGD500)
Study NCT01892475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-month follow up
Description: After the 4-month RCT, drivers will be incentivized to wear the step counter for another 3 months (i.e. Months 5 to 7) to test if effects of the rewards are sustained once the reward is no longer in place. For wearing their step counter and providing their step data, drivers will receive a modest cash incentive (amounting to SGD10) each month as well as the chance to win 1 of 3 cash prizes valued at SGD500.
Study NCT00308100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch 130/0.4
Description: HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
Study NCT00308100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Albumin
Description: 5% albumin, administered intra- and perioperatively
Study NCT00927745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoFlow mode on Evita 4 Dräger ventilators
Description: Activation of AutoFlow mode during assist-controlled ventilation
Study NCT00927745 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evita 4 Dräger ventilators
Description: Assist-controlled ventilation without activation of AutoFlow mode
Study NCT02680691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot, then conventional training
Description: Robot assisted gait training from the baseline, then conventional gait training at 4 weeks after baseline
Study NCT02680691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, then robot training
Description: Conventional gait training from the baseline, then robot assisted gait training at 4 weeks after baseline
Study NCT06146244 — intervention group
Intervention type: PROCEDURE
Intervention: sinus lift
Description: Implant placement on grafted sinus vs antral autogenous bone
Study NCT06146244 — intervention group
Intervention type: DEVICE
Intervention: resonance frequency analysis
Description: analysis of the ISQ evolution and its changes after 3 months of placing the implant in native or regenerated bone, always in the antral area
Study NCT01961635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implants
Description: place implant according fabricant guidelines, 2mm sub-crestally
Study NCT01546415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desferasirox
Description: Initial Dose: 20 mg/kg/d. Dose modification according to protocol.
Study NCT01975844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Anemia Mangement Protocol
Description: Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP .
Study NCT02081794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored education intervention
Description: Receive 2 minute video-assisted intervention on the risk and prevention of falls with tailored hand-outs depending on participant answers about fall risks
Study NCT02081794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard fall care
Description: Patient are given a generic handout on falling and receive standard care by nurses comprising of a fall risk assessment and verbal education
Study NCT04321837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coral Complex 3
Description: Coral-derived calcium supplement fortified with vitamin D3
Study NCT04321837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: Bisphosphonate
Study NCT04321837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Oral vitamin D3
Study NCT01049555 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Actigraphy and video recording signal
Description: Actigraphy and video recording signal during 1 hour
Study NCT01961635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia abutments
Description: place zirconia abutment on the day of implant placement
Study NCT01961635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium Abutments
Description: place titanium abutment on the day of implant placement
Study NCT01961635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cad-cam acrylic abutments
Description: place cad-cam acrylic abutment on the day of implant placement
Study NCT01961635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcrestal
Description: place implant 2mm below crestal bone
Study NCT01961635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: platform-switch
Description: abutment platform is narrow than implant diameter
Study NCT01961635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one-time one-abutment
Description: place the final abutment on the day of surgery and not remove it
Study NCT01961635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Torque 20 n/cm2
Description: the amount of torque applied to the abutment
Study NCT01033175 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: maximal cardiopulmonary exercise testing
Description: Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).
Study NCT01033175 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: peripheral blood samples
Description: Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.
Study NCT03788889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine infusion
Study NCT03788889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: Phenobarbital intravenous injection
Study NCT03788889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Standard of Care
Study NCT03788889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam
Description: Standard of Care
Study NCT03788889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo A
Description: Placebo injection
Study NCT03788889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo A
Description: Placebo injection
Study NCT03788889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo B
Description: Placebo infusion
Study NCT03788889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo B
Description: Placebo infusion
Study NCT04795271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthopedic intervention
Description: In each custom insole, modifications can be included in the following aspects according to the requirements of each participant :~1. Forefoot specifications: a) Retrocapital bar, b) Retrocapital support, c) Claw toe correction element, d) Pronating wedge, e) Supinator wedge, f) Metatarsal head pad, g) Selective perforations in the insole, h) Others.~2. Midfoot specifications: a) Internal arch, b) External arch, c) Full support, d) Excavations, e) Others.~3. Hindfoot specifications: a) Heel cup, b) Supinator wedge, c) Pronating wedge, d) Lifter, e) Cup, f) Others.~4. Insole type and lining material~5. Materials of the added corrections~6. Insole base: a) soft ethylene vinyl acetate (eva), b) semi-soft eva, c) hard eva, d) rubber, e) cuerolite.
Study NCT04244474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A single one ml injection
Description: All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).
Study NCT04244474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A single one ml injection
Description: All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 \[18\], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).
Study NCT02348164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pink grapefruit first followed by tangerines two weeks later
Description: A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later
Study NCT02348164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tangerines first followed by pink grapefruit two weeks later
Description: A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
Study NCT04485403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 800 mg/day ( 2 x 400mg) for 3 weeks in women with a bodyweight \<70 kg, and a dose of 1200 mg/day (3x400mg) in women weighing> 70kg. The effects of treatment will be compared on the basis of changes in the hormonal profile and inflammatory markers, as well as the clinical assessment of the patient.
Study NCT03868436 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methoxyflurane 3mL
Description: As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
Study NCT04116359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02771067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid infusion
Description: Fluid infusion will be performed using 6% hydroxyethyl starch. Pulse pressure variation and stroke volume will be measured before and after fluid infusion.
Study NCT04116359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT04116359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV
Study NCT04116359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molibresib
Description: Given PO
Study NCT04116359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molibresib Besylate
Description: Given PO
Study NCT02341976 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vibratory platform exercises
Description: Different positions on vibratory platform with different frequencies
Study NCT02684591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters
Study NCT02684591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03778216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Treatment
Study NCT01923181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily oral administration as tablets.
Study NCT03314116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guidance on auditory protection
Description: by video or medic
Study NCT01265914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FP-01.1
Description: Ascending doses of FP-01.1 will be administered
Study NCT00730067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: Sildenafil 50 mg three times daily
Study NCT01923181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
Study NCT01923181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo
Description: Once-daily oral administration as tablets.
Study NCT02240082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based COPing with Shiftwork Program
Description: COPing with Shift Work is an interactive, web-based program designed specifically for law enforcement officers to assist with the management of health and lifestyle challenges associated with shift work. The program will contain modules on sleep, physical activity, and nutrition in order to improve the health and safety of law enforcement officers and reduce their risk of chronic diseases associated with shift work. These modules will contain interactive assessments and cutting-edge scientific information on sleep, nutrition, and physical activity. Based on user input, officers will receive personalized feedback, tools, and strategies
Study NCT02855060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic Binder
Study NCT00730067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
Study NCT04333277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Patients with major depression (both sexes) will receive capsules with 1 × 10\^9 CFUs of Lactobacillus helveticus in addition to a conventional antidepressant treatment for 8 weeks.
Study NCT01265914 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04333277 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Patients with major depression (both sexes) will receive capsules of placebo (maltodextrin) in addition to a conventional antidepressant treatment for 8 weeks
Study NCT02042482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10U, L-carnitine
Study NCT02375412 — intervention group
Intervention type: PROCEDURE
Intervention: Pre-operative measurement of heart rate variability
Description: Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery
Study NCT04121962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentor
Description: Participants will be trained to be Peer Mentors and promote home-based testing to their social network
Study NCT04121962 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Website only
Description: Participants will be given instructions on how to use the project website to request kits to test for HIV at home and collect specimens for lab testing.
Study NCT04409756 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: shoulder rating questionnaire
Description: to investigate reliability of turkish version of shoulder rating questionnaire
Study NCT00335244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: 150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
Study NCT00335244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of intravenous L-citrulline
Description: Placebo of intravenous L-citrulline
Study NCT01638416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood transfusion
Description: Blood transfusion in ICU patients aged 18 and over.
Study NCT01638416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Blood transfusion in ICU patients aged 18 and over.
Study NCT03243916 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TACE plus Cyber knife
Description: Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
Study NCT04842240 — intervention group
Intervention type: PROCEDURE
Intervention: Pre- or sub-pectoral implant based immediate breast reconstruction
Description: All study participants will undergo skin sparing mastectomy (with or without nipple preservation) for breast cancer or for risk reduction. Patients will undergo immediate breast reconstruction using an implant or a tissue expander. The device will be placed in pre- or sub-pectoral plane which will be supported by mesh (Tiloop/Surgimend Acellular Dermal Matrix) and/or a dermal flap.